Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.

@article{Vallera1995TherapyFO,
  title={Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.},
  author={Daniel A. Vallera and Patricia A. Taylor and Angela Panoskaltsis-Mortari and Bruce R Blazar},
  journal={Blood},
  year={1995},
  volume={86 11},
  pages={4367-75}
}
A new pharmacologic agent, anti-CD3F(ab')2-ricin toxin A chain (RTA), was synthesized for the purpose of targeting T cells and as a means of treating established graft-versus-host disease (GVHD). The Fc region of anti-CD3 monoclonal antibody (MoAb) was removed to prevent its ability to activate T cells. The resulting F(ab')2 fragments were conjugated to deglycosylated RTA (dgRTA), a catalytic and potent phytotoxin. The resulting immunotoxin (IT) was potent (greater than 95% inhibition) and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Srinivasahar K: In vivo T cell ablation by a holo-immunotoxin directed at human CD3

  • Neville DM, J Scharff
  • Proc Natl Acad Sci USA
  • 1992

Successful treatment of human acute T-cell leukemia in SCID mice using anti-CD7-deglycosylated ricin A-chain immunotoxin DA7

  • J Kersey
  • Cancer Res
  • 1992

Similar Papers

Loading similar papers…